// App-Quantinova.ai

3994 : Immune competent syngeneic models demonstrate additive effects of combination strategies using checkpoint immunotherapy and inducers of immunogenic cell death (ICD)

Researchers

Presenter

  • Andrew Mckenzie

Principal Investigators

  • Rajendra Kumari

  • Qian Shi

  • Nektaria Papadopoulou

  • Yinfei Yin

  • Simon Jiang

  • Jane Wrigley

  • Jason King

  • Neil Williams

  • Russell Garland

Medical Centers

  • Crown Bioscience UK, Loughborough, United Kingdom

  • Crown Bioscience Inc, USA, CA

  • KWS Biotest, Bristol, United Kingdom.

Locations

  • United States

  • United Kingdom

Companies

  • Crown Bioscience Inc

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Cluster of Differentiation 4

  • Cluster of differentiation 8A

Drug/Treatment

  • Mitoxantrone

  • Doxorubicin

  • Bortezomib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved